Why the SEC Is Cracking Down on Drug Company Insiders and Crypto Platforms

The Securities and Exchange Commission charged George Demos, a former safety official at Acadia Pharmaceuticals, with insider trading on March 7, 2025. The allegation: he bought and sold company stock based on information about an upcoming FDA decision that hadn't been made public yet.

Demos worked in drug safety—a job that gave him early warning signs about whether the FDA was going to approve a new drug or reject it. When the FDA says no to a drug, that company's stock usually drops sharply. Because Demos knew this was coming before anyone else, he had a huge advantage over ordinary investors who made their trades without that inside knowledge.

Separate Charges Against Crypto Trading Sites

At the same time, the SEC charged two cryptocurrency platforms—Morocoin Tech Corp. and Berge Blockchain—with stealing $14 million from everyday investors. These platforms promised high returns and asked people to put money in without being properly licensed to do so.

This is part of a larger pattern. These crypto platforms did what unlicensed brokers have always done: take people's money while operating outside the rules that protect investors. Because crypto is still fairly new, many people don't realize these sites weren't playing by the same regulatory rulebook as traditional stock brokers.

How the SEC Helps You Avoid Scams

The SEC runs a program called PAUSE—which stands for Public Alerts for Unregistered Soliciting Entities. It's basically a public database of known fraudulent investment outfits that claim to be licensed when they're not.

You can check PAUSE if you're unsure whether an investment opportunity is legitimate. It's a straightforward tool: if a company or platform shows up on that list, stay away.

Why This Matters

The pharmaceutical insider trading case points to something worth flagging: when a company executive has privileged information that could move a stock price by 10, 20, or 30 percent in a single day, the game becomes unfair for regular investors. You can do all your research, but you're still competing against someone who knows something you can't possibly know.

The crypto enforcement actions show that the SEC is applying old investment rules to new technology. A decade ago, the agency had no experience with crypto platforms. Now it's saying: if you take customer money to buy and sell assets, you need a license, whether you're a traditional broker or a crypto site. That's a significant shift in how the agency regulates digital assets.

These cases follow a familiar pattern from earlier booms in technology. During the dot-com bubble in 2000, we saw waves of insider trading prosecutions when executives with access to non-public information about their companies' problems traded their stock before the truth came out. We're seeing something similar now as biotech and artificial intelligence investments grow, and as crypto markets mature. Periods of rapid growth and new technologies tend to attract people who exploit information advantages.

What the Rules Actually Say

The law allows the SEC to charge people with securities violations in two ways. The first covers careless or dishonest statements in stock trades. The second requires proof of intentional wrongdoing or reckless disregard for the truth. The second carries a higher bar—prosecutors have to prove the person knew what they were doing was wrong.

For the crypto cases, the SEC's argument is straightforward: these platforms accepted customer money to trade assets, which means they should have registered as brokers. They didn't. That's a violation of securities law, whether the assets are stocks or cryptocurrency.

Looking Ahead

From a practical standpoint, pharmaceutical companies now know they need strict policies around when employees can buy or sell stock—especially around the times when FDA decisions are pending. The crypto enforcement sends a message: just because something is digital and new doesn't mean it's exempt from the rules.

The broader context here is that the SEC is trying to keep up with how investment fraud adapts to new technologies. Fraud itself is not new. The methods change—today it's crypto platforms, yesterday it was over-the-counter penny stocks, before that it was boiler-room operations. The core problem stays the same: people with information advantages exploiting that advantage against ordinary investors. What's changed is the agency's capacity to pursue cases across both traditional markets and digital assets at the same time.